



SuperGen to Webcast Analyst & Investor Day

DUBLIN, Calif., May 19 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) today announced that it will webcast its Analyst & Investor Day live via the internet on Thursday, May 25, 2006 at 9:00 am EDT.

SuperGen's management will provide a general corporate update and a detailed look at the expanded drug discovery capabilities and assets gained as a result of the acquisition of Montigen Pharmaceuticals, Inc. The program will include a scientific review of several kinase inhibitors now in development and an overview of the CLIMB™ discovery process.

The live webcast, including the slide presentation, will be available in the Investor Relations section of the Company's website at <http://www.supergen.com>. This event webcast will be archived for 90 days.

About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen's portfolio includes Orathecin™ (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent® (pentostatin for injection), Mitomycin, and Surface Safe® cleaner. In addition, a number of aurora-A, tyrosine kinase and DNA methyltransferase inhibitors are under development. For more information about SuperGen, please visit <http://www.supergen.com>.

Contacts:

SuperGen

Timothy L. Enns

S.V.P., Corporate Communications
& Business Development

Tel: (925) 560-0100 x111

E-mail: tenns@supergen.com

Noonan Russo

Sharon Weinstein

Director of Investor Relations

Tel: (212) 845-4271

E-mail: sharon.weinstein@eurorscg.com

SOURCE SuperGen, Inc.

Web site: <http://www.supergen.com>

(SUPG)